// STATE LEGISLATION TRACKER

California AB 2442: Peptides.

⚖️ MIXED for peptide users 👤 LOW user impact 📜 Status: In committee

State: California
Bill: AB 2442
Session: 20252026
Filed: 2026-02-20
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

California AB2442 no longer directly opens a peptide access program; the latest text creates a state working group to study regulated research and investigational therapeutic access for peptides and novel compounds. It could shape future rules for medically supervised peptide use, but it does not currently change prescribing, compounding, telehealth, NP, or naturopath scope.

Key Points

No immediate new patient access pathway is created
CDPH working group would study regulated peptide access
Report with recommendations due by January 1, 2029
Scheduled controlled substances are excluded from the novel compound definition
No clear change to 503A/503B compounding or telehealth prescribing

What to Watch For

✓

Opportunity The study could lead to a future state-authorized pathway for safer, medically supervised peptide access.

Concern Future recommendations could add testing, reporting, or institutional limits that raise costs or narrow access.

Note The latest bill text is study-and-report focused, not an operational access program.

Note Watch whether NP, naturopath, pharmacy, and telehealth representatives are added to the working group.

Where the Bill Stands

AB2442 was held under submission in committee on May 14, 2026, so it has not advanced out of committee.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws